Lancet
-
Randomized Controlled Trial Multicenter Study Comparative Study
Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.
Fractional flow reserve (FFR) or non-hyperaemic pressure ratios are recommended to assess functional relevance of intermediate coronary stenosis. Both diagnostic methods require the placement of a pressure wire in the coronary artery during invasive coronary angiography. Quantitative flow ratio (QFR) is an angiography-based computational method for the estimation of FFR that does not require the use of pressure wires. We aimed to investigate whether a QFR-based diagnostic strategy yields a non-inferior 12-month clinical outcome compared with an FFR-based strategy. ⋯ Medis Medical Imaging Systems and Aarhus University.
-
Randomized Controlled Trial Multicenter Study
Effectiveness, cost-effectiveness, and positive externalities of integrated chronic care for adults with major depressive disorder in Malawi (IC3D): a stepped-wedge, cluster-randomised, controlled trial.
In low-income and middle-income countries, individuals with major depressive disorder often do not receive screening and treatment. We assessed effectiveness and cost-effectiveness of an integrated care model for treating major depressive disorder in Malawi, accounting for two sets of positive externalities: household benefits and improvements in comorbidities. ⋯ National Institute of Mental Health.
-
Despite the initial hope inspired by the 2015 Paris Agreement, the world is now dangerously close to breaching its target of limiting global multiyear mean heating to 1·5°C. Annual mean surface temperature reached a record high of 1·45°C above the pre-industrial baseline in 2023, and new temperature highs were recorded throughout 2024. The resulting climatic extremes are increasingly claiming lives and livelihoods worldwide. The Lancet Countdown: tracking progress on health and climate change was established the same year the Paris Agreement entered into force, to monitor the health impacts and opportunities of the world’s response to this landmark agreement. Supported through strategic core funding from Wellcome, the collaboration brings together over 300 multidisciplinary researchers and health professionals from around the world to take stock annually of the evolving links between health and climate change at global, regional, and national levels. The 2024 report of the Lancet Countdown, building on the expertise of 122 leading researchers from UN agencies and academic institutions worldwide, reveals the most concerning findings yet in the collaboration’s 8 years of monitoring. ⋯ With climate change breaking dangerous new records and emissions persistently rising, preventing the most catastrophic consequences on human development, health, and survival now requires the support and will of all actors in society. However, data suggest that engagement with health and climate change could be declining across key sectors: the number of governments mentioning health and climate change in their annual UN General Debate statements fell from 50% in 2022 to 35% in 2023, and only 47% of the 58 NDCs updated as of February, 2024, referred to health (indicator 5.4.1). Media engagement also dropped, with the proportion of newspaper climate change articles mentioning health falling 10% between 2022 and 2023 (indicator 5.1). The powerful and trusted leadership of the health community could hold the key to reversing these concerning trends and making people’s wellbeing, health, and survival a central priority of political and financial agendas. The engagement of health professionals at all levels of climate change decision making will be pivotal in informing the redirection of efforts and financial resources away from activities that jeopardise people’s health towards supporting healthy populations, prosperous economies, and a safer future. As concerning records continue to be broken and people face unprecedented risks from climate change, the wellbeing, health, and survival of individuals in every country now hang in the balance.
-
Monkeypox virus clade I is endemic in several central African countries and characterised by an increase in disease severity and mortality. Since October, 2023, a large-scale mpox outbreak has emerged in DR Congo, and in March, 2024, the first individuals with mpox were reported outside the endemic areas in Republic of the Congo. We aimed to provide insight into the epidemic by sequencing samples obtained from individuals with mpox in Republic of the Congo. ⋯ Intramural Research Program of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.